

# ASURAGEN TUMOR BANK FREQUENTLY ASKED QUESTIONS

## FAQs

---

### **Do you source other clinical indications or pathologies besides cancer?**

The bank is comprised of over 100,000 FFPE specimens spanning 100 discrete cancer types. In contrast, other indications, including autoimmune and inflammatory diseases are not represented in the bank.

---

### **Do you offer FFPE specimens for non-human tissues?**

Our FFPE specimens currently consist of human tissue only.

---

### **Do you have material other than FFPE specimens available in the bank?**

Currently, we only offer formalin-fixed, paraffin-embedded specimens and are unable to provide plasma and serum. Please contact us if you are interested in matched frozen tissue samples.

---

### **Can you provide normal adjacent tissue?**

Our tumor bank is limited to patient tumor biopsies or resections and does not include normal adjacent tissue collected in separate blocks or matched normals (e.g. matched plasma).

---

### **Where are the specimens sourced from?**

The specimens were collected at various hospitals and testing centers across the United States and Canada from 1992 to 2010. We do not have additional information with regards to the actual testing site.

---

### **Do you offer Tissue Microarrays (TMAs)?**

No, we do not prepare TMAs from our specimens. In order to maintain the highest integrity, we prefer to keep the block intact without removing any slices from the tissue.

---

### **Can you provide the pathology report?**

Although we are unable to provide pathology reports, our database does contain the pathologist review notes and will be provided upon receiving your request.

---

### **Do you offer guarantees?**

We do not offer any guarantees on the specimens. Please contact us for additional details.

---

### **Pricing?**

Each quote is custom. Please contact us for additional details.

---

## FAQs

---

### What information are you able to provide with the specimens?

The database includes the following information for the majority of the specimens:

- Age
- Gender
- Pathologist review notes and comments including clinical diagnosis
- Prior treatment (reported as true or false)
- Site of tumor
- Primary/Secondary tumor (reported as P or S)
- Clinical diagnosis
- Collection date
- Basic histology (% tumor, % necrosis, path comments)
- Extreme Drug Resistance (EDR) Assay data\*
- Differential Staining Cytotoxicity (DiSC) Assay data\*
- Ploidy information\*
- FISH\* (EGFR and Her2 status only)
- IHC\* (e.g. MDR-1, P53, Her2, Cathespin D, EGFR, PR & ER Receptor, Thrombospondin 1, BCL-2, Pan Cytokeratin)
- Noted whether appeared to contain low material upon physical inspection and inventorying

\*Not provided in all cases

---

### Is there any information that you are unable to provide?

- Stage and/or grade (provided for a few cases)
  - Disease outcome or treatment information
  - Tobacco use
  - Images of H&E slides (provided for a few cases)
  - Raw data from IHC and FISH
- 

### Can you provide patient information/informed consent template?

As part of our agreement with the clinical testing laboratory from which we procured the specimens, we did not receive any blocks until they had 1) matured for a period of five years and 2) all identifiers or identifiers linked to the subject were removed. As such, we are unable to provide patient information other than what is listed above.

---

For more information about tumor inventory and pricing  
Contact | [tumorbank@asuragen.com](mailto:tumorbank@asuragen.com)



Asuragen, Inc.  
2150 Woodward Street, Suite 100  
Austin TX 78744  
[asuragen.com](http://asuragen.com)

3000-0530

Three thick, curved lines in blue, dark blue, and orange sweep across the bottom right corner of the page.